Literature DB >> 1753337

Postexposure chemoprophylaxis with ZDV or ZDV combined with interferon-alpha: failure after inoculating rhesus monkeys with a high dose of SIV.

F Fazely1, W A Haseltine, R F Rodger, R M Ruprecht.   

Abstract

Presently, no information is available regarding the efficacy of chemoprophylaxis in controlled human trials following accidental exposure to the human immunodeficiency virus (HIV). Using the closely related simian immunodeficiency virus (SIV) in rhesus monkeys, which develop a disease closely resembling human AIDS, we tested the efficacy of either single-agent 3'-azido-3'-deoxythymidine (ZDV) or the combination of ZDV plus recombinant human interferon-alpha (IFN-alpha). Treatment was started 3 h following inoculation of a high dose of SIV and continued for 21 days. SIV-inoculated control animals remained untreated. Virus was recovered from all monkeys on day 8, and by week 7 all had seroconverted. In contrast to monkeys treated with ZDV alone, animals given combination therapy had lower levels of p27 gag antigen compared to untreated controls on day 8 (p = 0.043). We conclude that neither treatment regimen could prevent infection after high-dose virus exposure; however, combination therapy may have depressed the level of virus replication more effectively than ZDV alone.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1753337

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  8 in total

1.  Evidence that high-dosage zidovudine at time of retrovirus exposure reduces antiviral efficacy.

Authors:  L E Mathes; K A Hayes; G Kociba
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

2.  Comparison of the effects of 3'-azidothymidine with those of neutralizing antibodies on simian immunodeficiency virus infection in macrophages.

Authors:  M F McEntee; C Flexner; H Farzadegan; P Pitha; O Narayan
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

Review 3.  Human immunodeficiency virus and hepatitis--implications for operating room personnel.

Authors:  S Colbert; G J Sheehan
Journal:  Ir J Med Sci       Date:  1995-01       Impact factor: 1.568

4.  Feline immunodeficiency virus infection: plasma, but not peripheral blood mononuclear cell virus titer is influenced by zidovudine and cyclosporine.

Authors:  J Meers; G M del Fierro; R B Cope; H S Park; W K Greene; W F Robinson
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

5.  Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors.

Authors:  K Uberla; C Stahl-Hennig; D Böttiger; K Mätz-Rensing; F J Kaup; J Li; W A Haseltine; B Fleckenstein; G Hunsmann; B Oberg
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-29       Impact factor: 11.205

6.  Simian immunodeficiency virus (SIV) infection of infant rhesus macaques as a model to test antiretroviral drug prophylaxis and therapy: oral 3'-azido-3'-deoxythymidine prevents SIV infection.

Authors:  K K Van Rompay; M L Marthas; R A Ramos; C P Mandell; E K McGowan; S M Joye; N C Pedersen
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

7.  Effects of U-75875, a peptidomimetic inhibitor of retroviral proteases, on simian immunodeficiency virus infection in rhesus monkeys.

Authors:  L N Martin; K F Soike; M Murphey-Corb; R P Bohm; E D Roberts; T J Kakuk; S Thaisrivongs; T J Vidmar; M J Ruwart; S R Davio
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

8.  Preclinical assessment of HIV vaccines and microbicides by repeated low-dose virus challenges.

Authors:  Roland R Regoes; Ira M Longini; Mark B Feinberg; Silvija I Staprans
Journal:  PLoS Med       Date:  2005-07-19       Impact factor: 11.069

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.